TY - JOUR
T1 - Sirtuin 2–mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses
AU - Kosciuczuk, Ewa M.
AU - Mehrotra, Swarna
AU - Saleiro, Diana
AU - Kroczynska, Barbara
AU - Majchrzak-Kita, Beata
AU - Lisowski, Pawel
AU - Driehaus, Caroline
AU - Rogalska, Anna
AU - Turner, Acara
AU - Lienhoop, Thomas
AU - Gius, David R
AU - Fish, Eleanor N.
AU - Vasilopoulos, Athanasios
AU - Platanias, Leonidas C.
N1 - Funding Information:
This work was supported in part by National Institutes of Health Grants CA77816 and CA155566 and Grant I01CX000916 from the Department of Veterans Affairs. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This article contains Figs. S1–S3 and Tables S1–S4. The NCBI GEO accession number for the microarray data reported in this paper is GSE66033. 1 Both authors contributed equally to this work. 2 Supported in part by National Institutes of Health, NCI Grant T32 CA080621. 3 Supported by Narodowe Centrum Nauki (NCN) 2016/22/M/NZ2/0054. 4 Tier 1 Canada Research Chair. 5 Supported by National Institutes of Health, NCI Grant R01CA182506. 6To whom correspondence should be addressed: Robert H. Lurie Compre-hensive Cancer Center, 303 East Superior St., Lurie 3–125, Chicago, IL 60611. E-mail: l-platanias@northwestern.edu.
PY - 2019/1/18
Y1 - 2019/1/18
N2 - Type I interferons (IFNs) induce expression of multiple genes that control innate immune responses to invoke both antiviral and antineoplastic activities. Transcription of these interferon-stimulated genes (ISGs) occurs upon activation of the canonical Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathways. Phosphorylation and acetylation are both events crucial to tightly regulate expression of ISGs. Here, using mouse embryonic fibroblasts and an array of biochemical methods including immunoblotting and kinase assays, we show that sirtuin 2 (SIRT2), a member of the NAD-dependent protein deacetylase family, is involved in type I IFN signaling. We found that SIRT2 deacetylates cyclin-dependent kinase 9 (CDK9) in a type I IFN– dependent manner and that the CDK9 deacetylation is essential for STAT1 phosphorylation at Ser-727. We also found that SIRT2 is subsequently required for the transcription of ISGs and for IFN-driven antiproliferative responses in both normal and malignant cells. These findings establish the existence of a previously unreported signaling pathway whose function is essential for the control of JAK–STAT signaling and the regulation of IFN responses. Our findings suggest that targeting sirtuin activities may offer an avenue in the development of therapies for managing immune-related diseases and cancer.
AB - Type I interferons (IFNs) induce expression of multiple genes that control innate immune responses to invoke both antiviral and antineoplastic activities. Transcription of these interferon-stimulated genes (ISGs) occurs upon activation of the canonical Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathways. Phosphorylation and acetylation are both events crucial to tightly regulate expression of ISGs. Here, using mouse embryonic fibroblasts and an array of biochemical methods including immunoblotting and kinase assays, we show that sirtuin 2 (SIRT2), a member of the NAD-dependent protein deacetylase family, is involved in type I IFN signaling. We found that SIRT2 deacetylates cyclin-dependent kinase 9 (CDK9) in a type I IFN– dependent manner and that the CDK9 deacetylation is essential for STAT1 phosphorylation at Ser-727. We also found that SIRT2 is subsequently required for the transcription of ISGs and for IFN-driven antiproliferative responses in both normal and malignant cells. These findings establish the existence of a previously unreported signaling pathway whose function is essential for the control of JAK–STAT signaling and the regulation of IFN responses. Our findings suggest that targeting sirtuin activities may offer an avenue in the development of therapies for managing immune-related diseases and cancer.
UR - http://www.scopus.com/inward/record.url?scp=85060148444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060148444&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA118.005956
DO - 10.1074/jbc.RA118.005956
M3 - Article
C2 - 30487288
AN - SCOPUS:85060148444
SN - 0021-9258
VL - 294
SP - 827
EP - 837
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 3
ER -